SERF2

Across TCGA pan-cancer cohorts, SERF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SERF2 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SERF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SERF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where SERF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.813	0.312	.008	6	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.585	.040	4	view →
HNSC	DFS	Quartile	II,III,IV	0.921	1.000	.033	2	view →
CCRCC	DFS	Median	III,IV	0.689	0.431	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SERF2–PDAC (DFS)

Open the PDAC breakdown →